Overview
Telemedi provides a platform for telemedicine that enables remote medical consultations, online prescriptions, and sick-leave documentation for business clients such as insurers and travel-assistance companies, with a white-label option. Patients can access the service online from anywhere in eight languages to connect with doctors across multiple specialties. It differentiates itself by focusing on B2B partnerships and offering white-labeled integration into partners’ platforms, rather than primarily consumer-facing apps. Its goal is to help insurers and travel-assistance providers offer seamless, worldwide telemedicine support to their customers under their own brand.
Work here?Claim your company
Simplify's take
What believers are saying
- UNIQA said in 2024 Telemedi processes around 70,000 medical enquiries monthly.
- Mavie rolled Telemedi into Austria, Serbia, Montenegro, Croatia, and Bosnia in 2024.
- Telemedi is hiring AI and GTM engineers in 2026, signaling active product expansion.
What critics are saying
- Telemedi depends on Mavie for strategy; control shifts away from founder Pawel Sieczkiewicz.
- Telemedicine reimbursement rules remain political; any Poland or Austria restriction hits bookings immediately.
- Insurers can switch vendors quickly, and white-label commoditization crushes pricing by 2027.
What makes Telemedi unique
- Telemedi’s B2B white-label model embeds telemedicine into insurers and assistance platforms.
- Mavie’s 2023 majority stake gave Telemedi distribution into Austria and CEE.
- Telemedi offers 24/7 multilingual consultations, prescriptions, and sick leave across several countries.
Help us improve and share your feedback! Did you find this helpful?